{"@id":"https://bioecon.ru/technology/fetal-sparing-antibody-engineering/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/fetal-sparing-antibody-engineering/","json":"https://cn.bioecon.ru/api/v1/technology/fetal-sparing-antibody-engineering/index.json"},"id":"fetal-sparing-antibody-engineering","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/genmab/","https://bioecon.ru/companies/jiangsu-hengrui-medicine/","https://bioecon.ru/companies/daiichi-sankyo/","https://bioecon.ru/companies/johnson-johnson/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/vland-biotech/","https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/e-square-environment-engineering-coltd/","https://bioecon.ru/companies/isomorphic-labs/"]},"maturity":7,"name":"不跨越胎盘屏障的胎儿免损抗体工程","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"酸性微环境FcRn结合位点敲除"},{"n":2,"title":"滋养层极性单层转运抑制评估"},{"n":3,"title":"离体人胎盘小叶双向灌注金标准"},{"n":4,"title":"母体药代与抗炎疗效确证"}],"summary":"通过工程化改造抗体Fc段，特异性阻断与胎盘合胞体滋养层新生儿Fc受体（FcRn）的内吞转运结合，实现治疗孕妇严重自身免疫性疾病的同时杜绝药物渗入胎儿循环。","url":"/technology/fetal-sparing-antibody-engineering/","verified":"2026-11-22"}